Protagonist Therapeutics Inc. added a new investor, Pharmstandard International SA, to its previously announced Series B financing, boosting its raise by $4 million, for a total of $18 million. The funds will support Protagonist’s pipeline of orally stable peptides for inflammatory bowel disease (IBD) and other gastrointestinal (GI) disorders.